

Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) Market in China 2021

<https://marketpublishers.com/r/C351DF781B37EN.html>

Date: March 2021

Pages: 22

Price: US\$ 450.00 (Single User License)

ID: C351DF781B37EN

Abstracts

The conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China in terms of revenue is set to grow by US\$ 442 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.8% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for conventional synthetic disease-modifying antirheumatic drugs (DMARDs). The China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market is segmented on the basis of type. By type, it is categorized into hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others.

The report has profiled some of the key players of the market such as AbbVie Inc., Johnson & Johnson International Inc., Pfizer Inc., Roche Holding AG, Sanofi S.A., Shanghai Pharmaceuticals Holding Co. Ltd., Sincere Pharmaceutical Group Limited, Sunshine Guojian Pharmaceuticals (Shanghai) Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: hydroxychloroquine, iguratimod, leflunomide, methotrexate, sulfasalazine, and others

Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market

Pinpoint growth sectors and trends for investment

Understand what the future of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China looks like

Identify the competitive landscape and window of opportunity

Contents

1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value

3.2 Market Value Forecast

4. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) MARKET BY TYPE

4.1 Hydroxychloroquine

4.2 Iguratimod

4.3 Leflunomide

4.4 Methotrexate

4.5 Sulfasalazine

4.6 Others

5. COMPANY PROFILES

5.1 AbbVie Inc.

5.2 Johnson & Johnson International, Inc.

5.3 Pfizer, Inc.

5.4 Roche Holding AG

5.5 Sanofi S.A.

5.6 Shanghai Pharmaceuticals Holding Co., Ltd.

5.7 Simcere Pharmaceutical Group Limited

5.8 Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd.

5.9 Zhejiang Hisun Pharmaceutical Co., Ltd.

6. APPENDIX

6.1 About StrategyHelix

6.2 Disclaimer

I would like to order

Product name: Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) Market in China 2021

Product link: <https://marketpublishers.com/r/C351DF781B37EN.html>

Price: US\$ 450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C351DF781B37EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

